9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

# EPHA2 Human

*EPH Receptor A2 Human Recombinant*
*RCP0762*

## Product Overview

| | |
|---|---|
| Name | EPHA2 Human |
| **Description** | |
| EPH Receptor A2 Human Recombinant | |
| Accession (Primary) | P29317 |
| **Synonyms** | |
| EPHA2, EPH Receptor A2, ECK, Tyrosine-Protein Kinase Receptor ECK, EC 2.7.10.1, CTRCT6, ARCC2, CTPP1, CTPA, Epithelial Cell Receptor Protein Tyrosine Kinase, Ephrin Type-A Receptor 2, Soluble EPHA2 Variant 1, Epithelial Cell Kinase, EC 2.7.10, EphA2. | |
| **Introduction** | |
| EPH Receptor A2 (EPHA2) is a member of the ephrin receptor subfamily of the protein-tyrosine kinase family. EPHA2 is a protein which binds ephrin-A ligands. EPH and EPH-related receptors are associated with mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily normally have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into two groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. EPHA2 gene mutations are the cause of certain genetically-related cataract disorders. | |
| **Source** | |
| HEK 293. | |
| **Physical Appearance** | |
| Filtered White lyophilized (freeze-dried) powder. | |
| **Formulation** | |
| EPHA2 was filtered (0.4 μm) and lyophilized from 0.5mg/ml solution in phosphate buffered saline and 5% (w/v) trehalose. | |
| **Stability** | |
| Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C. | |
| **Purity** | |

9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

Greater than 95.0% as determined by SDS-PAGE.

**Amino acid sequence**

AQGKEVVLLD FAAAGGELGW LTHPYGKGWD LMQNIMNDMP IYMYSVCNVM SGDQDNWLRT NWVYRGEAER IFIELKFTVR DCNSFPGGAS SCKETFNLYY AESDLDYGTN FQKRLFTKID TIAPDEITVS SDFEARHVKL NVEERSVGPL TRKGFYLAFQ DIGACVALLS VRVYYKKCPE LLQGLAHFPE TIAGSDAPSL ATVAGTCVDH AVVPPGGEEP RMHCAVDGEW LVPIGQCLCQ AGYEKVEDAC QACSPGFFKF EASESPCLEC PEHTLPSPEG ATSCECEEGF FRAPQDPASM PCTRPPSAPH YLTAVGMGAK VELRWTPPQD SGGREDIVYS VTCEQCWPES GECGPCEASV RYSEPPHGLT RTSVTVSDLE PHMNYTFTVE ARNGVSGLVT SRSFRTASVS INQTEPPKVR LEGRSTTSLS VSWSIPPPQQ SRVWKYEVTY RKKGDSNSYN VRRTEGFSVT LDDLAPDTTY LVQVQALTQE GQGAGSKVHE FQTLSPEKL H HHHHH .

**Solubility**

It is recommended to add deionized water to prepare a working stock solution of approximately 0.5 mg/ml and let the lyophilized pellet dissolve completely. EPHA2 is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.

**Precautions**

EPHA2 Human is for research use only and not for use in diagnostic or therapeutic procedures.

## Target Information: ( P29317 )